Treatment of newly diagnosed multiple myeloma

  • Antonio Palumbo
  • Valeria Magarotto
  • Alessandra Larocca
  • Sara Bringhen
  • Patrizia Falco
  • Francesco Di Raimondo
  • Luca Baldini
  • Mario Boccadoro
Article
  • 55 Downloads

Abstract

Multiple myeloma (MM) is the second most common oncohematologic disease. Most patients are older than 65 years at diagnosis, and different therapeutic options are available depending on the age of the patient. For those younger than 65 years, autologous stem cell transplantation is the standard of care, whereas in older patients the better choice is conventional chemotherapy. The introduction of thalidomide, bortezomib, and lenalidomide, which target MM cells and the bone marrow microenvironment, has changed the therapeutic options in newly diagnosed patients with MM.

References and Recommended Reading

  1. 1.
    Barlogie B, Kyle RA, Anderson KC, et al.: Standard chemotherapy compared with high dose chemoradiotherapy for multiple myeloma: final results of phase III US intergroup trial S9321. J Clin Oncol 2006, 24:929–936.PubMedCrossRefGoogle Scholar
  2. 2.
    Alexanian R, Barlogie B, Tucker S: VAD-based regimens as primary treatment of multiple myeloma. Am J Hematol 1990, 33:86–89.PubMedCrossRefGoogle Scholar
  3. 3.
    Cavallo F, Boccadoro M, Palumbo A: Review of thalidomide in the treatment of newly diagnosed multiple myeloma. Ther Clin Risk Manage 2007, 3:1–10.CrossRefGoogle Scholar
  4. 4.
    Rajkumar SV, Blood E, Vesole D, et al.: Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24:431–436.PubMedCrossRefGoogle Scholar
  5. 5.
    Rajkumar SV, Hussein M, Catalano J, et al.: A multicenter, randomized, double-blind, placebo-controlled trial of thalidomide plus dexamethasone versus dexamethasone alone as initial therapy for newly diagnosed multiple myeloma [abstract 795]. J Clin Oncol 2006, 24:426s.CrossRefGoogle Scholar
  6. 6.
    Cavo M, Zamagni E, Tosi P, et al.: Superiority of thalidomide and dexamethasone over vincristine-doxorubicin dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005, 106:35–39.PubMedCrossRefGoogle Scholar
  7. 7.
    Macro M, Divine M, Uzunhan Y, et al.: Dexamethasone + thalidomide (Dex/Thal) compared to VAD as pre-transplant treatment in newly diagnosed MM: a randomized trial [abstract]. Blood 2006, 108:57a.CrossRefGoogle Scholar
  8. 8.
    Barlogie B, Tricot G, Anaissie E, et al.: Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006, 354:1021–1030.PubMedCrossRefGoogle Scholar
  9. 9.
    Goldschmidt H, Sonneveld P, Breitkreutz I, et al.: HOVON 50/GMMGHD3-trial: phase III study on the effect of thalidomide combined with high dose melphalan in myeloma patients up to 65 years [abstract]. Blood 2005, 106:128a.Google Scholar
  10. 10.
    Zangari M, Barlogie B, Anaissie E, et al.: Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 2004, 126:715–721.PubMedCrossRefGoogle Scholar
  11. 11.
    Rajkumar SV: Thalidomide therapy and deep venous thrombosis in multiple myeloma. Mayo Clinic Proc 2005, 80:1549–1551.Google Scholar
  12. 12.
    Baz R, Li L, Kottke-Marchant K, et al.: The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 2005, 80:1549–1551.CrossRefGoogle Scholar
  13. 13.
    Naina HVK, Lacy MQ, Dispenzieri A, et al.: Incidence and clinical course of peripheral neuropathy in patients receiving thalidomide for the treatment of multiple myeloma [abstract]. Blood 2005, 106:970a.Google Scholar
  14. 14.
    Dimopoulos MA, Anagnostopoulos A, Terpos E, et al.: Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma. Haematologica 2006, 91:252–254.PubMedGoogle Scholar
  15. 15.
    Abdelkefi A, Torjman L, Ben Romdhane N, et al.: First-line thalidomide-dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (<61 years) with symptomatic multiple myeloma. Bone Marrow Transplant 2005, 36:193–198.PubMedCrossRefGoogle Scholar
  16. 16.
    Anderson K, Richardson P, Chanan-Khan AA, et al.: Single agent bortezomib in previously untreated multiple myeloma: results of a phase II multicenter study [abstract]. J Clin Oncol 2006, 24:423s.Google Scholar
  17. 17.
    Jagannath S, Durie B, Wolf J, et al.: Bortezomib therapy alone and in combination with dexamethasone for patients with previously untreated multiple myeloma [abstract]. Blood 2005, 106:231a.Google Scholar
  18. 18.
    Harousseau J-L, Attal M, Leleu X, et al.: Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results from an IFM phase II study. Haematologica 2006, 91:1498–1505.PubMedGoogle Scholar
  19. 19.
    Harousseau J-L, Marit G, Caillot D, et al.: Velcade/dexamethasone (Vel/Dex) versus VAD as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM). An interim analysis of the IFM 2005-01 randomized multicenter phase III trial [abstract]. Blood 2006, 108:21a.Google Scholar
  20. 20.
    Rosinol L, Oriol A, Mateos MV, et al.: Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics. J Clin Oncol 2007, 25:4452–4458.PubMedCrossRefGoogle Scholar
  21. 21.
    Oakervee HE, Popat R, Curry N, et al.: PAD combination therapy (PS341/bortezomib doxorubicin and examethasone) for previously untreated multiple myeloma. Br J Haematol 2005, 129:755–762.PubMedCrossRefGoogle Scholar
  22. 22.
    Popat R, Oakervee HE, Curry N, et al.: Reduced dose PAD combination therapy (PS341/bortezomib doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma [abstract]. Blood 2005, 106:717a.CrossRefGoogle Scholar
  23. 23.
    Wang M, Delasalle K, Giralt S, et al.: Rapid control of previously untreated multiple myeloma with bortezomibthalidomide-dexamethasone followed by early intensive therapy [abstract]. Blood 2005, 106:231a.Google Scholar
  24. 24.
    Richardson PG, Briemberg H, Jagannath S, et al.: Frequency, characteristics and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006, 24:3113–3120.PubMedCrossRefGoogle Scholar
  25. 25.
    San Miguel JF, Richardson P, Sonneveld P, et al.: Frequency, characteristics and reversibility of peripheral neuropathy (PN) in the APEX trial [abstract]. Blood 2005, 106:111a.Google Scholar
  26. 26.
    Lonial S, Richardson P, Sonneveld P, et al.: Haematologic profile in the phase III APEX trial [abstract]. Blood 2005, 106:97a.CrossRefGoogle Scholar
  27. 27.
    Lacy M, Gertz M, Dispenzieri A, et al.: Lenalidomide plus dexamethasone (Rev/Dex) in newly diagnosed multiple myeloma: response to therapy, time to progression and survival [abstract]. Blood 2006, 108:798a.Google Scholar
  28. 28.
    Rajkumar SV, Hajman SR, Lacy MQ, et al.: Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed multiple myeloma. Blood 2005, 106:4050–4053.PubMedCrossRefGoogle Scholar
  29. 29.
    Rajkumar V, Jacobus S, Callander N, et al.: Randomized phase III trial of lenalidomide plus high dose dexamethasone versus lenalidomide plus low dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group [abstract]. Blood 2006, 108:799a.Google Scholar
  30. 30.
    Niesvizky R, Jayabalan DS, Christos PJ, et al.: BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete-and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood 2008, 111:1101–1109.PubMedCrossRefGoogle Scholar
  31. 31.
    Ohara T, Morishita T, Suzuki H, et al.: Antibiotics directly induce apoptosis in B cell lymphoma cells derived from BALB/c mice. Anticancer Res 2004, 24:3723–3730.PubMedGoogle Scholar
  32. 32.
    Niesvizky R, Bergsagel P, Pearse RN, et al.: Claritromycin potentiates the response of dexamethasone in chemotherapy naïve multiple myeloma patients: a prospective, sequential, randomized trial [abstract]. Blood 2002, 1100:389b.Google Scholar
  33. 33.
    Mileshkin L, Prince HM: The adverse prognostic impact of advance age in multiple myeloma. Leuk Lymphoma 2005, 46:951–966.PubMedCrossRefGoogle Scholar
  34. 34.
    Alexanian R, Haut A, Khan AU, et al.: Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 1969, 208:1680–1685.PubMedCrossRefGoogle Scholar
  35. 35.
    Myeloma Trialists’ Cooperative Group: Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6633 patients from 27 randomized trials. J Clin Oncol 1998, 16:3832–3842.Google Scholar
  36. 36.
    Facon T, Mary J, Pegourie B, et al.: Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood 2006, 107:1292–1298.PubMedCrossRefGoogle Scholar
  37. 37.
    Palumbo A, Bringhen S, Caravita T, et al.: Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomized control trial. Lancet 2006, 367:825–831.PubMedCrossRefGoogle Scholar
  38. 38.
    Facon T, Mary JY, Hulin C, et al.: Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007, 370:1209–1218.PubMedCrossRefGoogle Scholar
  39. 39.
    Hulin C, Virion J, Leleu X, et al.: Comparison of melphalan-prednisone-thalidomide (MP-T) to melphalan-prednisone (MP) in patients 75 years of age or older with untreated multiple myeloma (MM). Preliminary results of the randomized, double-blind, placebo controlled IFM 01-01 trial [abstract]. J Clin Oncol 2007, 25(Suppl):8001.Google Scholar
  40. 40.
    Palumbo A, Bringhen S, Falco P, et al.: Time to first progression but not B2-microglobulin predicts outcome in myeloma patients who receive thalidomide as salvage therapy. Cancer 2007, 110:824–829.PubMedCrossRefGoogle Scholar
  41. 41.
    Ludwig H, Drach J, Tothova E, et al.: Thalidomide-dexamethasone vs melphalan prednisolone as first line treatment in elderly patients with multiple myeloma: an interim analysis [abstract]. Blood 2005, 106:231a.Google Scholar
  42. 42.
    Almond JB, Cohen GM: The proteasome: a novel target for cancer chemotherapy. Leukemia 2002, 16:433–443.PubMedCrossRefGoogle Scholar
  43. 43.
    Mateos MV, Hernandez JM, Hernandez MT, et al.: Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 2006, 108:2165–2172.PubMedCrossRefGoogle Scholar
  44. 44.
    Palumbo A, Falco P, Corradini P, et al.: Melphalan, prednisone and lenalidomide treamtent for newly diagnosed myeloma: a report from the GIMEMA-Italian Multiple Myeloma Network. J Clin Oncol 2007, 25:4458–4465.CrossRefGoogle Scholar
  45. 45.
    Palumbo A, Bringhen S, Petrucci MT, et al.: Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 2004, 104:3052–3057.PubMedCrossRefGoogle Scholar
  46. 46.
    Palumbo A, Bringhen S, Bertola A, et al.: Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m(2)). Leukemia 2004, 18:133–138.PubMedCrossRefGoogle Scholar
  47. 47.
    Berenson JR, Crowley J, Grogan TM, et al.: Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma. Blood 2002, 99:3163–3168.PubMedCrossRefGoogle Scholar
  48. 48.
    Attal M, Harousseau JL, Leyvraz S, et al.: Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006, 108:3289–3294.PubMedCrossRefGoogle Scholar
  49. 49.
    Spencer A, Prince M, Roberts AW, et al.: First analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) trial of thalidomide and alternate day prednisolone following autologous stem cell transplantation (ASCT) for patients with multiple myeloma (ALLG MM6) [abstract]. Blood 2006, 108:58a.Google Scholar
  50. 50.
    Abdelkefi A, Ladeb S, Torjman L, et al.: Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. Blood 2008, 111:1805–1810.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2008

Authors and Affiliations

  • Antonio Palumbo
    • 1
  • Valeria Magarotto
  • Alessandra Larocca
  • Sara Bringhen
  • Patrizia Falco
  • Francesco Di Raimondo
  • Luca Baldini
  • Mario Boccadoro
  1. 1.Divisione di Ematologia dell’Università di TorinoAzienda Ospedaliera S. Giovanni BattistaTorinoItaly

Personalised recommendations